Nuclear Medicine

Nuclear medicine (also called molecular imaging) includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. Nuclear imaging is achieved by injecting small amounts of radioactive material (radiopharmaceuticals) into patients before or during their scan. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

RSS icon
Thumbnail

New details emerge on looming medical isotope shortage

The supply of Mo-99 and Tc-99m—the most commonly utilized medical isotopes in the world—could be cut by as much as 40% until the reactor in the Netherlands is up and running again.

Warning: Sidelined reactor could trigger medical isotope shortage

The impending shortage pertains to molybdenum-99, or Mo-99. A structural issue has occurred with a pipe within the high-flux reactor in Petten, Netherlands, which will require an immediate repair. 

Video of Jamshid Maddahi, MD, UCLA, explaining why flurpiridaz will change cardiac imaging and increase the adoption of PET cardiac imaging.

A closer look at how FDA's flurpiridaz approval will impact nuclear cardiology

The newly approved PET radiotracer is expected to improve patient care significantly. “We have been able to reach the pinnacle of myocardial perfusion imaging with flurpiridaz," one expert said.

Theranostics GE HealthCAre

GE HealthCare touts its leading role in $27.8M initiative to expand theranostics use

Thera4Care aims to strengthen the adoption of radiology-based diagnostics and therapies, bringing together 29 stakeholders from across the care continuum. 

Banner ASC in Sun City, Arizona.

Low doses of radiation still increase risk of leukemia, lymphoma and myeloma

A new study found cumulative radiation exposure of 16 mSv to red bone marrow can cause an increased rate of some hematological malignancies.

Thumbnail

Radiopharmaceutical firm Pentixapharm raises $22M through initial public stock offering

Founded in 2019, the firm is focused on developing products for the diagnosis and therapy of blood cancers and other indications not addressed by nuclear medicine. 

AURORA trial results for Flurpiridaz F-18 PET vs. SPECT discussed by principal investigator Jamshid Maddahi, MD.

'This could be a paradigm shift': How PET with newly approved flurpiridaz compares to SPECT

GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview. 

Matthew Roden, PhD, president and CEO of Aktis Oncology

Radiopharmaceutical firm Aktis Oncology raises $175M in Series B financing

The Boston clinical stage biotechnology company is working to develop new products to treat a range of solid tumors. 

Displaying 49 - 56 of 355
Design by Adaptive Theme